### EORTC GROUPS SEMI-ANNUAL MEETING – WARSAW 2016

20 – 22 October 2016

AGENDA EORTC “Gastro-Intestinal Tract Cancer Group” MEETING

<table>
<thead>
<tr>
<th>Time slot</th>
<th>Topic / Title of presentation</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 14:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:00</td>
<td>Task Force: Pancreatic cancer</td>
<td>J-L. Van Laethem</td>
</tr>
<tr>
<td></td>
<td>(Room: TBD)</td>
<td></td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Task Force: Hepatobiliary cancer</td>
<td>M. Moehler</td>
</tr>
<tr>
<td></td>
<td>(Room: TBD)</td>
<td></td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>Task Force: Colorectal Cancer</td>
<td>G. Folprecht</td>
</tr>
<tr>
<td></td>
<td>(Room: TBD)</td>
<td></td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>Task Force: Esophago-gastric cancer</td>
<td>D. Wagner</td>
</tr>
<tr>
<td></td>
<td>(Room: TBD)</td>
<td>M. Moehler</td>
</tr>
<tr>
<td>17:00 – 18:00</td>
<td>EORTC-SPECTAcolor steering committee</td>
<td>G. Folprecht</td>
</tr>
<tr>
<td></td>
<td>(Room: TBD)</td>
<td></td>
</tr>
<tr>
<td><strong>Social event</strong></td>
<td><strong>(details to be confirmed)</strong></td>
<td></td>
</tr>
</tbody>
</table>

Thursday 20 October 2016
Centrum Onkologii-Instytut, Roentgena 5, Warsaw
### Friday 21 October 2016
Novotel Center Hotel, Warsaw

<table>
<thead>
<tr>
<th>Time slot</th>
<th>Topic / Title of presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:30</td>
<td>Business meeting (restricted to active members)</td>
<td></td>
</tr>
<tr>
<td>09:30 – 09:35</td>
<td>Welcome</td>
<td>M. Ducreux</td>
</tr>
<tr>
<td>09:35 – 09:50</td>
<td>Short report of the strategy meeting</td>
<td>M. Ducreux</td>
</tr>
<tr>
<td>09:50 – 10:10</td>
<td>SpectaColor</td>
<td>G. Folprecht, A. Roth, D. Arnold</td>
</tr>
<tr>
<td>10:10 – 11:00</td>
<td>Report from the Task Forces: CRC, Eso-Gastric, Pancreas, Hepato-Biliary</td>
<td>G. Folprecht et al., M. Moehler, D. Wagner et al., J. Van Laethem et al.</td>
</tr>
</tbody>
</table>

11:00 – 11:10  **Coffee Break**

**Ongoing protocols**

11:10 – 13:00
- EORTC 1203 INNOVATION
- EORTC 1409 CLIMB
- EORTC 1527 DREAM
- EORTC 22114-40111 TOP GEAR
- EORTC 1423 EVIDENCE
- EORTC 1316 InterAACT
- EORTC 40091 BOS2
- EORTC 40071 Lapatinib
- EORTC 40054 PETACC6

D. Wagner, S. Evrard, F. Lordick / K. Haustermans, S. Stroobants / J. Freire, D. Arnold, S. Benoist, M. Mauer, M. Mauer

13:00 – 14:00 **Lunch**
## EORTC GROUPS SEMI-ANNUAL MEETING – WARSAW 2016

20 – 22 October 2016

AGENDA EORTC “Gastro-Intestinal Tract Cancer Group” MEETING

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 15:30</td>
<td><strong>Protocol in development and new projects</strong></td>
</tr>
<tr>
<td></td>
<td>- EORTC 1418 MEGAN</td>
</tr>
<tr>
<td></td>
<td>- EORTC 1534 SAKK</td>
</tr>
<tr>
<td></td>
<td>- EORTC 1560 I-LOCC (new CLOCC)</td>
</tr>
<tr>
<td></td>
<td>- 1640 LASCCO</td>
</tr>
<tr>
<td></td>
<td>- 1614 CR Sequence</td>
</tr>
<tr>
<td></td>
<td>- 1607 ‘Open-label first line, randomized phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer (BTC)’</td>
</tr>
<tr>
<td></td>
<td>M. Knoedler</td>
</tr>
<tr>
<td></td>
<td>A. Roth / T. Koessler</td>
</tr>
<tr>
<td></td>
<td>T. Ruers</td>
</tr>
<tr>
<td></td>
<td>F. Lordick / C. Caballero</td>
</tr>
<tr>
<td></td>
<td>R. Salazar / D. Arnold</td>
</tr>
<tr>
<td></td>
<td>M. Moehler</td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>Young Investigators – Details to be determined</td>
</tr>
<tr>
<td>17:00 – 17:15</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td>18:00</td>
<td>Bus city tour</td>
</tr>
<tr>
<td>20:00</td>
<td>Diner</td>
</tr>
</tbody>
</table>
### Saturday 22 October 2015
#### Novotel Center Hotel, Warsaw

#### Session 1
Chairs: M. Ducreux, J. Regula

<table>
<thead>
<tr>
<th>Time slot</th>
<th>Topic / Title of presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 9:20</td>
<td>Less or more radiotherapy for rectal cancer</td>
<td></td>
</tr>
<tr>
<td>9:20 – 9:40</td>
<td>Peri-operative management of oesphago-gastric cancer: current data</td>
<td></td>
</tr>
<tr>
<td>9:40 – 10:00</td>
<td>Surveillance for upper GI cancers - who and how?</td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:20</td>
<td>To resect primary tumor or not in advanced GI cancers</td>
<td></td>
</tr>
<tr>
<td>10:20 – 10:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:40 – 11:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

#### Session 2
Chairs: F. Lordick, L. Wyrwicz

<table>
<thead>
<tr>
<th>Time slot</th>
<th>Topic / Title of presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:20</td>
<td>Rectal cancer: which patients still need chemoradiation?</td>
<td></td>
</tr>
<tr>
<td>11:20 – 11:40</td>
<td>Immunotherapy in advanced GI cancers: current data and perspectives</td>
<td></td>
</tr>
<tr>
<td>11:40 – 12:00</td>
<td>Which frontline treatment for which patient with stage IV CRC</td>
<td></td>
</tr>
<tr>
<td>12:00 – 12:20</td>
<td>How to selected patients for ablative therapy in mCRC</td>
<td></td>
</tr>
<tr>
<td>12:20 – 12:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:40 – 13:00</td>
<td>Closing remarks</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>